Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Segment Information - Additional Information (Details)

v3.22.1
Segment Information - Additional Information (Details)
€ in Thousands
 12 Months Ended
Dec. 31, 2021
EUR (€)
Customer
Segment
Dec. 31, 2020
EUR (€)
Customer
Dec. 31, 2019
Customer
Disclosure of operating segments [line items]      
Number of segments | Segment 2    
Number of external customers exceeds10% group's revenue | Customer 0 0  
Percentage of revenues increased 27.50% 23.40%  
Increase in revenue from contract with customer € 181,883 € 125,498  
Total assets 1,418,842 967,979  
Total liabilities 577,183 657,839  
Unallocated Amounts      
Disclosure of operating segments [line items]      
Total assets 279,342 2,396  
Total liabilities € 77,603 € 217,890  
Reportable Segments      
Disclosure of operating segments [line items]      
Number of segments | Segment 2    
Biopharmaceutical and Diagnostic Solutions      
Disclosure of operating segments [line items]      
Segment sales percentage 82.00% 85.00%  
Number of external customers exceeds10% group's revenue | Customer     1
Number of customers more than 10% of segment revenue | Customer 1    
Percentage of operating profit margin 21.40% 18.10%  
Percentage of gross profit margin 33.10% 29.60% 26.80%
Biopharmaceutical and Diagnostic Solutions | Operating Segments      
Disclosure of operating segments [line items]      
Percentage of revenues increased 22.80% 24.10%  
Increase decrease in revenue € 129,145 € 110,105  
Total assets 885,733 776,832  
Total liabilities € 335,919 € 330,624  
Engineering      
Disclosure of operating segments [line items]      
Segment sales percentage 18.00% 15.00%  
Number of customers more than 10% of segment revenue | Customer 1    
Percentage of operating profit margin 10.50% 10.80%  
Percentage of gross profit margin 19.30% 20.90% 18.00%
Engineering | Operating Segments      
Disclosure of operating segments [line items]      
Percentage of revenues increased 42.60% 20.70%  
Increase decrease in revenue € 65,428 € 26,310  
Total assets 253,767 188,751  
Total liabilities € 163,661 € 109,325  
Bottom of Range | Drug Containment Systems      
Disclosure of operating segments [line items]      
Segment sales percentage 50.00%